Phase II trial of durvalumab (MEDI4736) with/without tremelimumab for advanced hepatocellular carcinoma after palliative hypofractionated radiotherapy.
| Autor: | Andemicael, Luchia, Chang, Hewitt, Anwar, Moshiur Mekhail, Bauer, Kelly, Gordan, John, Johnson, Jamese, Keenan, Bridget P, Venook, Alan P., Wang, Chia-Ching Jackie, Zhang, Karen, Fong, Lawrence, Kelley, Robin Kate, Feng, Mary Uan-Sian |
|---|---|
| Zdroj: | Journal of Clinical Oncology; 2/1/2023 Supplement 1, Vol. 41, pTPS630-TPS630, 1p |
| Databáze: | Supplemental Index |
| Externí odkaz: |
|